Statin/fusidic acid interaction highlighted

Rhabdomyolysis causes the release of damaging myoglobin molecules into the bloodstream | SCIENCE PHOTO LIBRARY
Rhabdomyolysis causes the release of damaging myoglobin molecules into the bloodstream | SCIENCE PHOTO LIBRARY

The MHRA has reminded prescribers of the increased risk of rhabdomyolysis when systemic fusidic acid (Fucidin) is used at the same time as a statin. The exact mechanism of this interaction is unknown and it could therefore occur with some, or all, statins.

The MHRA has issued the following advice:

  • Systemic fusidic acid should not be given with statins.
  • When the use of systemic fusidic acid is essential, statins should be discontinued. They may be restarted 7 days after the last dose of fusidic acid.
  • In exceptional cases requiring prolonged systemic fusidic acid treatment, the need for a statin should be assessed on an individual basis and only undertaken with close medical supervision.
  • Patients should be advised to seek medical advice immediately if they experience muscle weakness, pain or tenderness.
  • Any muscle symptoms reported in patients who are prescribed statins should be followed up.

MHRA Drug Safety Update – September 2011

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more